-
Innovation Ranking
NewInnovation Ranking – MaxCyte Inc
MaxCyte Inc (MaxCyte) discovers, manufactures, and commercializes cell-based medicines. The company’s products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin-targeted therapy for treating ovarian and peritoneal mesothelioma; and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for...
-
Company Insights
Innovation and Patenting activity of MaxCyte Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of MaxCyte Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Chronic Granulomatous Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Granulomatous Disease - Drugs In Development, 2023’, provides an overview of the Chronic Granulomatous Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Granulomatous Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate Gp91Phox For Chronic Granulomatous Disease in Chronic Granulomatous Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate Gp91Phox For Chronic Granulomatous Disease in Chronic Granulomatous Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gp91 Grans...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Metastatic Colorectal Cancer Drug Details: Palbociclib (Ibrance) is a...
-
Company Profile
MaxCyte Inc – Company Profile
MaxCyte Inc (MaxCyte) discovers, manufactures, and commercializes cell-based medicines. The company’s products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin-targeted therapy for treating ovarian and peritoneal mesothelioma, and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Activate gp91phox for Chronic Granulomatous Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Gene Therapy to Activate gp91phox for Chronic Granulomatous Disease Drug Details Gene therapy is...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.